Peptides, multimers and polymers

Handbook of Experimental Pharmacology

Volumn 185, Issue PART2, 2008, Pages 61-92

  Dijkraaf, I ^a   Wester, H J ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC AGENT; PEPTIDE; POLYMER; RADIOPHARMACEUTICAL AGENT; RECEPTOR;

ANIMAL; BINDING SITE; CHEMICAL STRUCTURE; HUMAN; ISOTOPE LABELING; METABOLISM; POSITRON EMISSION TOMOGRAPHY; PROTEIN BINDING; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYNTHESIS; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; BINDING SITES; BIOLOGICAL TRANSPORT; HUMANS; ISOTOPE LABELING; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PEPTIDES; POLYMERS; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; RADIOPHARMACEUTICALS; RECEPTORS, PEPTIDE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 52049089468     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-540-77496-9_4     Document Type: Article

References (160)

1. Adair BD, Yeager M (2002) Three-dimensional model of the human platelet integrin ?IIb?3 based on electron cryomicroscopy and x-ray crystallography. Proc Natl Acad Sci USA 99: 14059-14064
2. Alberto R, Abram U (2003) 99mTc: Labeling Chemistry and Labeled Compounds. A. Vertes, S. Nagy and Z. Klencsar (eds) Handbook of Nuclear Chemistry-Vol. 4, 211-256
3. Alberto R (2007) The particular role of radiopharmacy within bioorganicmetallic chemistry. J Organomet Chem 692:1179-1186
4. Anderson SA, Rader RK, Westlin WF et al (2000) Magnetic resonance contrast enhancement of neovasculature with alpha(v)beta(3)-targeted nanoparticles. Magn Reson Med 44:433-439
5. Arnold M, Cavalcanti-Adam E-A, Glass R et al (2004) Activation of integrin function by nanopatterned adhesive interfaces. Chem Phys Chem 5:383-388
6. Bakker WH, Breeman WA, van der Pluijm ME, de Jong M, Visser TJ, Krenning EP (1996) Iodine-131 labelled octreotide: not an option for somatostatin receptor therapy.Eur J Nucl Med 23(7):775-781
7. Barret P, MacDonald A, Helliwell R, Davidson G, Morgan P (1994) Cloning and expression of a new member of the melanocyte-stimulating hormone receptor family. J Mol Endocrinol 12:203-213
8. Beer AJ, Haubner R, Sarbia M, Goebel M, Luderschmidt S, Grosu AL, Schnell O, Niemeyer M, Kessler H, Wester HJ, Weber WA, Schwaiger M (2006) Positron emission tomography using [18F]Galacto-rgd identifies the level of v3 expression in man. Clin Cancer Res 12:3942-3949
9. BeheM, Behr TM (2002) Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies. Biopolymers 66: 399-418
10. Behe M, Becker W, Gotthardt M, Angerstein C, Behr TM (2003) Improved kinetic stability of DTPA-Dglu as compared with monofunctional DTPA in chelating indium and yttrium: preclinical and initial clinical evaluation of radiometal labeled minigastrin derivatives. Eur J Nucl Med Mol Imaging 30:1140-1146
11. Behr TM, Jenner N, Radetzky S et al (1998) Targeting of cholecystokinin-B/gastrin receptors in vivo: preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabeled gastrin. Eur J Nucl Med 25:424-430
12. Behr TM, Jenner N, Behe M et al (1999) Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors. J Nucl Med 40:1029-1044
13. Bodei L, Cremonesi M, Grana C, Rocca P, Bartolomei M, Chinol M, Paganelli G (2004) Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 31:1038-1046
14. Boturyn D, Coll J-L, Garanger E, Favrot M-C, Dumy P (2004) Template assembled cyclopeptides as multimeric systems for integrin targeting and endocytosis. J Amer Chem Soc 126:5730-5739
15. Breeman WA, de Jong M, Kwekkeboom DJ, Valkema R, Bakker WH, Kooij PP, Visser TJ, Krenning EP (2001) Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur J Nucl Med 28:1421-1429
16. Breeman WAP, de Jong M, Erion JL, Bugaj JE, Srinivasan A, Bernard BF, Kwekkeboom DJ, Visser TJ, Krenning EP (2002) Preclinical comparison of 111In-labeled DTPA-or DOTAbombesin analogs for receptor-targeted scintigraphy and radionuclide therapy. J Nucl Med 43:1650-1656
17. Buchsbaum DJ (2004) Imaging and therapy of tumors induced to express somatostatin receptor by gene transfer using radiolabeled peptides and single chain antibody constructs. Sem Nucl Med 34:32-46
18. Buchsbaum DJ, Chaudhuri TR, Yamamoto M, Zinn KR (2004) Gene expression imaging with radiolabeled peptides. Ann Nucl Med 18:275-283
19. Burkhart DJ, Kalet BT, Coleman MP, Post GC, Koch TH (2004) Doxorubicin-formaldehyde conjugates targeting alphavbeta3 integrin. Mol Cancer Ther 3:1593-1604
20. Carraway R, Leeman SE (1973) The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami. J Biol Chem 248:6854-6861
21. Chen J, Cheng Z, Hoffman TJ, Jurisson SS, Quinn TP (2000) Melanoma-targeting Properties of 99mTechnetium-labeled cyclic -melanocyte-stimulating hormone peptide analogues. Cancer Res 60:5649-5658
22. Chen X, Hou Y, Tohme M et al (2004a) Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression. J Nucl Med 45:1776-1783
23. Chen X, Liu S, Hou Y, Tohme M, Park R, Bading JR et al (2004b) MicroPET imaging of breast cancer v-integrin expression with 64Cu-labeled dimeric RGD peptides. Mol Imaging Biol 6:350-359
24. Chen X, Park R, Hou Y, Tohme M, Shahinian AH, Bading JR, Conti PS (2004c) MicroPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts. J Nucl Med 45:1390-1397
25. Chen X, Park R, Shahinian AH, Bading JR, Conti PS (2004d) Pharmacokinetics and tumor retention of 125I-labeled RGD peptide are improved by PEGylation. Nucl Med Biol 31:11-19
26. Chen X, Tohme M, Park R, Hou Y, Bading JR, Conti PS (2004e) Micro-PET imaging of v3-integrin expression with 18F-labeled dimeric RGD peptide. Mol Imaging 3:96-104
27. Cheng Z, Chen J, Miao Y, Owen NK, Quinn TP, Jurisson SS (2002) Modification of the structure of a metallopeptide: synthesis and biological evaluation of J Med Chem45:3048-3056
28. Cone RD, Mountjoy KG, Robbins LS et al (1993) Cloning and functional characterization of a family of receptors for the melanotropin peptides. Ann N Y Acad Sci 680:342-363
29. de Jong M, Bakker WH, Krenning EP, Breeman WA, van der Pluijm ME, Bernard BF, Visser TJ, Jermann E, Behe M, Powell P, Macke HR (1997) Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med 24:368-371
30. de Jong M, Bakker WH, Bernard BF et al (1999) Preclinical and initial clinical evaluation of 111In-labeled nonsulfated CCK8 analog: a peptide for CCK-B receptor-targeted scintigraphy and radionuclide therapy. J Nucl Med 40: 2081-2087
31. de Jong M, BreemanWA, Bernard BF, Bakker WH, Schaar M, van Gameren A, Bugaj JE, Erion J, Schmidt M, Srinivasan A, Krenning EP (2001) [177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer 92:628-633
32. de Jong M, Kwekkeboom D, Valkema R, Krenning EP (2003) Radiolabelled peptides for tumour therapy: current status and future directions. Plenary lecture at the EANM 2002. Eur J Nucl Med Mol Imaging 30:463-469
33. De Visser M, Janssen PJJM, Srinivasan A, Reubi JC, Waser B, Erion JL, Schmidt MA, Krenning EP, De JongM(2003) Stabilised 111In-labelled DTPA-and DOTA-conjugated neurotensin analogues for imaging and therapy of exocrine pancreatic cancer. Eur J Nucl Med Mol Imaging 30:1134-1139
34. De Visser M, VanWeerden WM, De Ridder CM, Reneman S,Wildeman N, Melis M, Krenning EP, De Jong M (2005) Androgen regulation of GRP receptor-expression in human prostate tumor xenografts. J Nucl Med 46:396P
35. Desarnaud F, Labbe O, Eggerickx D, Vassart G, Parmentier M (1994) Molecular cloning, functional expression and pharmacological characterization of a mouse melanocortin receptor gene. Biochem J 299:366-373
36. Dubey PK, Mishra V, Jain S, Mahor S, Vyas SP (2004). Liposomes modified with cyclic RGD peptide for tumor targeting. J Drug Target 12:257-264
37. Dumont Y, Thakur M, Beck-Sickinger A, Fournier A, Quirion R (2003) Development and characterization of a highly selective neuropeptide Y Y5 receptor agonist radioligand: [125I][hPP1-17, Ala31, Aib32]NPY. Br J Pharmacol 139:1360-1368
38. Dumont Y, Thakur M, Beck-Sickinger A, Fournier A, Quirion R (2004) Characterization of a new neuropeptide Y Y5 agonist radioligand: [125I][cPP(1-7), NPY(19-23), Ala31, Aib32, Gln34]hPP. Neuropeptides 38:163-174
39. Fathi Z, Iben LG, Parker EM (1995) Cloning, expression, and tissue distribution of a fifth melanocortin receptor subtype. Neurochem Res 20:107-113
40. Feng Y, Broder CC, Kennedy PE, Berger EA (1996) HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272: 872-877
41. Ferrari M (2005) Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 5: 161-171
42. Froidevaux S, Calame-Christe M, Schuhmacher J, Tanner H, Saffrich R, Henze M, Eberle AN (2004) A gallium-labeled DOTA-?-melanocyte-stimulating hormone analog for PET imaging of melanoma metastases. J Nucl Med 45:116-123
43. Fujii N, Oishi S, Hiramatsu K, Araki T, Ueda S, Tamamura H, Otaka A, Kusano S, Terakubo S, Nakashima H, Broach JA, Trent JO, Wang ZX, Peiper SC (2003) Molecular-size reduction of a potent CXCR4-chemokine antagonist using orthogonal combination of conformation-and sequence-based libraries. Angew Chem Int Ed 42:3251-3253
44. Gantz I, Konda Y, Tashiro T, Shimoto Y, Miwa H, Munzert G, Watson SJ, Del Valle V, Yamada T (1993a) Molecular cloning of a novel melanocortin receptor. J Biol Chem 268:8246-8250
45. Gantz I, Miwa H, Konda Y, Shimoto Y, Tashiro T, Watson SJ, Del Valle V, Yamada T (1993b) Molecular cloning, expression, and gene localization of a fourth melanocortin receptor. J Biol Chem 268:15174-15179
46. Garcia-Garayoa E, Maes V, Blauenstein P, Blanc A, Hohn A, Tourwe D, Schubiger PA (2006) Double-stabilized neurotensin analogues as potential radiopharmaceuticals for NTR-positive tumors. Nucl Med Biol 33:495-503
47. Garg PK, Alston KL, Zalutsky MR (1995) Catabolism of radioiodinated murine monoclonal antibody F(ab-)2 fragment labeled using N-succinimidyl 3-iodobenzoate and Iodogen methods. Bioconjug Chem 6:493-501
48. Gehlert DR (1999) Role of hypothalamic neuropeptide Y in feeding and obesity. Neuropeptides 33:329-338
49. Giblin MF, Wang N, Hoffman TJ, Jurisson SS, Quinn TP (1998) Design and characterization of ?-melanotropin peptide analogs cyclized through rhenium and technetium metal coordination. Proc Natl Acad Sci U S A 95:12814-12818
50. Ginj M, Zhang H, Waser B, Cescato R, Wild D, Wang X, Erchegyi J, Rivier J, Macke HR, Reubi JC (2006) Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci U S A 103:16436-16441
51. Gotthardt M, Fischer M, Holz JB, Jungclas H, Fritsch HW, Behe M et al (2002) Use of the incretin hormone glucagon-like peptide-1 (GLP-1) for the detection of insulinomas: first experimental results. Eur J Nucl Med Mol Imaging 29: 597-606
52. Gotthardt M, Behe MP, Beuter D, Battmann A, Bauhofer A, Schurrat T, Schipper M, Pollum H, Oyen WJG, Behr TM (2006) Improved tumour detection by gastrin receptor scintigraphy in patients with metastasised medullary thyroid carcinoma. Eur J Nucl Med Mol Imag 33: 1273-1279
53. Gotthardt M, Lalyko G, van Eerd-Vismale J, Keil B, Schurrat T, Hower M, Laverman P, Behr TM, Boerman OC, Goke B, BeheM(2006b) A new technique for in vivo imaging of specific GLP-1 binding sites: First results in small rodents. Regul Pept 137:162-167
54. Gottschalk K-E, Adams PD, Brunger AT, Kessler H (2002) Transmembrane signal transduction of the ?IIb?3 integrin. Protein Science11:1800-1812
55. Grundemar L, Bloom SR (1997) Neuropeptide Y and drug developments, vol 396. Academic Press, San Diego
56. Hajitou A, Pasqualini R, Arap W (2006) Vascular targeting: recent advances and therapeutic perspectives. Trends Cardiovasc Med 16:80-88
57. Hanaoka H, Mukai T, Tamamura H, Mori T, Ishino S, Ogawa K, Iida Y, Doi R, Fujii N, Saji H (2006) Development of a 111In-labeled peptide derivative targeting a chemokine receptor, CXCR4, for imaging tumors. Nucl Med Biol 33:489-494
58. Handl HL, Vagner J, Han H, Mash E, Hruby VJ, Gillies RJ (2004) Hitting multiple targets with multimeric ligands. Expert Opin Ther Targets 8:565-586
59. Haubner R, Wester H-J (2004) Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies. Curr Pharm Des 10:1439-1455
60. Haubner R, Wester HJ, Reuning U, Senekowitsch-Schmidtke R, Diefenbach B, Kessler H et al (1999) Radiolabeled v3 integrin antagonists: a new class of tracers for tumor targeting. J Nucl Med 40:1061-1071
61. Haubner R, Wester HJ, Burkhart F, Senekowitsch-Schmidtke R, Weber W, Goodman SL, Kessler H, Schwaiger M (2001) Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med 42:326-336
62. Haubner R, Kuhnast B, Mang C, Weber WA, Kessler H, Wester HJ, Schwaiger M (2004) [18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjugate Chem 15:61-69
63. Haubner R, Weber WA, Beer AJ et al (2005) Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS Med. 2:244-254
64. Hennig IM, Laissue JA, Horisberger U, Reubi JC (1995) Substance P receptors in human primary neoplasms. Int J Cancer 61:786-792
65. Henze M, Schuhmacher J, Hipp P, Kowalski J, Becker DW, Doll J, Macke HR, Hofmann M, Debus J, Haberkorn U (2001) PET imaging of somatostatin receptors using [68GA]DOTA-DPhe1-Tyr3-octreotide: first results in patients with meningiomas. J Nucl Med 42:1053-1056
66. Hofmann M, Maecke H, Borner R, Weckesser E, Schoffski P, Oei L, Schumacher J, Henze M, Heppeler A, Meyer J, Knapp H (2001) Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med 28:1751-1757
67. Hruby VJ, Sharma SD, Toth K, Jaw JY, Al-Obeidi F, Sawyer TK, Hadley ME (1993) Design, synthesis, and conformation of superpotent and prolonged acting melanotropins. Ann N Y Acad Sci 680:51-63
68. Huhalov A, Chester KA (2004) Engineered single chain antibody fragments for radioimmunotherapy. Q J Nucl Med Mol Imaging 48:279-288
69. Hultsch C, Pawelke B, Bergmann, Wuest F (2006) Synthesis and evaluation of novel multimeric neurotensin(8-13) analogs. Bioorg Med Chem 14:5913-5920
70. Janssen ML, Oyen WJ, Dijkgraaf I, Massuger LF, Frielink C, Edwards DS et al (2002a) Tumor targeting with radiolabeled v?3 integrin binding peptides in a nude mouse model. Cancer Res 62:6146-6151
71. Janssen MLH, Oyen WJG, Massuger LFAG, Frielink C, Dijkgraaf I, Edwards DS et al (2002b) Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor imaging. Cancer Biother Radiopharm 17:641-646
72. Kessler H, Haupt A, Schudok M (1988) structural optimization of peptides for cytoprotection of rat liver cells. In: Shiba T, Sakakibara S (eds) Peptide chemistry 1987 (Proc Jpn Symp Peptide Chem, Sept. 28-Oct. 2, 1987, Kobe, Japan). Protein Research Foundation, Osaka, pp 627-630
73. Kessler H, Schudok M, Haupt A (1989) Dimerization of cyclic hexapeptides: strong increase of biological activity. In: Jung G, Bayer E (eds) Peptides 1988 (Proc 20th Eur Peptide Symp, Sept. 4-9, 1988, Tubingen). Walter de Gruyter, Berlin New York, pp 664-666
74. Kiessling LL, Gestwicki JE, Strong LE (2000) Synthetic multivalent ligands in the exploration of cell-surface interactions. Curr Opin Chem Biol 6:696-703
75. Kneifel S. Cordier D, Good S, Ionescu MCS, Ghaffari A, Hofer S, Kretzschmar M, Tolnay M, Apostolidis C, Waser B, Arnold M, Mueller-Brand J, Maecke HR, Reubi JC, Merlo A (2006) Local targeting of malignant gliomas by the diffusible peptidic vector 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid-substance P. Clin Cancer Res 12: 3843-3850
76. Korner M, Waser B, Reubi JC (2004a) Neuropeptide Y receptor expression in human primary ovarian neoplasms. Lab Invest 84:71-80
77. Korner M, Waser B, Reubi JC (2004b) High expression of NPY receptors in tumors of the human adrenal gland and extraadrenal paraganglia. Clin Cancer Res 10:8426-8433
78. Koglin N, Anton M, Hauser A, Saur D, Algul H, Schmid R, Gansbacher B, Schwaiger M, Wester HJ (2006) CXCR4 chemokine receptor SPECT/PET imaging with radiolabeled CPCR4: a promising approach for imaging metastatic processes. J Nucl Med 47(Suppl 1):505P
79. Kok RJ, Schraa AJ, Bos EJ et al (2002) Preparation and functional evaluation of RGD-modified proteins as alpha(v)beta(3) integrin directed therapeutics. Bioconjug Chem 13:128-135
80. Koivunen E, Wang B, Ruoslahti E (1995) Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins. Biotechnology (N Y) 13:265-270
81. Komazawa H, Saiki I, Aoki M et al (1993a) Synthetic Arg-Gly-Asp-Ser analogues of the cell recognition site of fibronectin that retain antimetastatic and anti-cell adhesive properties. Biol Pharm Bull 16:997-1003
82. Komazawa H, Saiki I, Igarashi Y et al (1993b) The conjugation of RGDS peptide with CMchitin augments the peptide-mediated inhibition of tumor metastasis. Carbohydrate Polymers 21: 299-307
83. Komazawa H, Saiki I, Nishikawa N et al (1993c) Inhibition of tumor metastasis by Arg-Gly-Asp-Ser (RGDS) peptide conjugated with sulfated chitin derivative, SCM-chitin-RGDS. Clin Exp Metastasis 11:482-491
84. Kramer RH, Karpen JW (1998) Spanning binding sites on allosteric proteins with polymer-linked ligand dimers. Nature 395:710-713
85. Krantic S, Goddard I, Saveanu A, Giannetti N, Fombonne J, Cardoso A, Jaquet P, Enjalbert A (2004) Novel modalities of somatostatin actions. Eur J Endocrinol 151:643-655
86. Kraus JL, Menassa P (1987) Effect of new biologically active polypeptides on dihexadecyl phosphate vesicles. Pharmacol Res Commun 19:469-77
87. Kraus JL, DiPaola A, Belleau B (1984) Cyclic tetrameric clusters of chemotactic peptides as superactive activators of lysozyme release from human neutrophils. Biochem Biophys Res Commun 124:939-944
88. Krenning EP, Bakker WH, Breeman WA, Koper JW, Kooij PP, Ausema L, Lameris JS, Reubi JC, Lamberts SW (1989) Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet 1(8632):242-244
89. Krenning EP, Kwekkeboom DJ, Valkema R, Pauwels S, Kvols LK, De Jong M (2004) Peptide receptor radionuclide therapy. Ann N Y Acad Sci 1014:234-245
90. Kroog GS, Jensen RT, Battey JF (1995) Mammalian bombesin receptors. Med Res Rev 15: 389-417
91. Kwekkeboom DJ, Bakker WH, Kooij PPM et al (2000) Cholecystokinin receptor imaging using an octapeptide DTPA-CCK analogue in patients with medullary thyroid carcinoma. Eur J Nucl Med 27:1312-17
92. Kwekkeboom DJ, Bakker WH, Kooij PP, KonijnenbergMW, Srinivasan A, Erion JL,Schmidt MA, Bugaj JL, de Jong M, Krenning EP (2001) [177Lu-DOTAOTyr3] octreotate: comparison with [111In-DTPAo]octreotide in patients. Eur J Nucl Med 28:1319-1325
93. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK, O'dorisio TM, Valkema R, Bodei L, Chinol M, Maecke HR, Krenning EP (2005) Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 46(Suppl 1):62S-66S
94. Labbe O, Desarnaud F, Eggerickx D, Vassart G, Parmentier M (1994) Molecular cloning of a mouse melanocortin 5 receptor gene widely expressed in peripheral tissues. Biochemistry 33:4543-4549
95. Landon LA, Zou J, Deutscher SL (2004) Is phage display technology on target for developing peptide-based cancer drugs? Curr Drug Discov Technol. 2004 Jan; 1(2):113-132
96. Langer M, La Bella R, Garcia-Garayoa E, Beck-Sickinger AG (2001) Bioconjugate Chem12:1028-1034
97. Lantry LE, Cappelletti E, Maddalena ME, Fox JS, Feng W, Chen J, Thomas R, Eaton SM, Bogdan NJ, Arunachalam T, Reubi JC, Raju N, Metcalfe C, Lattuada L, Linder KE, Swenson RE, Tweedle MF, Nunn AD (2006) 177Lu-AMBA: synthesis and characterization of a selective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer. J Nucl Med 47:1144-1152
98. Li R, Babu CR, Lear JD, Wand AJ, Bennett JS, DeGrado WF (2001) Oligomerization of the integrin ?IIb?3: roles of the transmembrane and cytoplasmic domains. Proc Natl Acad Sci U S A 98:12462-12467
99. Li W, Metcalf DG, Gorelik R et al (2005) A push-pull mechanism for regulating integrin function. Proc Natl Acad Sci U S A 102:1424-1429
100. Luo Y, Prestwich GD (2002) Cancer-targeted polymeric drugs. Curr Cancer Drug Targets 2: 209-226
101. Luyt LG, Katzenellenbogen JA (2002) A trithiolate tripodal bifunctional ligand for the radiolabeling of peptides with gallium(III). Bioconjug Chem 13:1140-1145
102. Maecke HR, Hofmann M, Haberkorn U (2005) (68)Ga-labeled peptides in tumor imaging. J Nucl Med 46(Suppl 1):172S-178S
103. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K (2000) Tumor vascular permeability and the EPReffect in macromolecular therapeutics: a review. J Control Release 65:271-284
104. Maeda H, Fang J, Inutsuka T, Kitamoto Y (2003) Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. Int Immunopharmacol 3: 319-328
105. Maina T, Nock BA, Zhang H, Nikolopoulou A, Waser B, Reubi JC, Maecke HR (2005) Species differences of bombesin analog interactions with GRP-R define the choice of animal models in the development of GRP-R-targeting drugs. J Nucl Med 46:823-830
106. Mammen M, Choi SK, Whitesides M (1998) Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors. Angew Chem Int Ed 37: 2754-2794
107. Matsuoka T, Hirakawa K, Chung YS et al (1998) Adhesion polypeptides are useful for the prevention of peritoneal dissemination of gastric cancer. Clin Exp Metastasis 16:381-388
108. Meisetschlager G, Poethko T, Stahl A, Wolf I, Scheidhauer K, Schottelius M, Herz M, Wester HJ, Schwaiger M (2006) Gluc-Lys([18F]FP)-TOCA PET in patients with SSTR-positive tumors: biodistribution and diagnostic evaluation compared with [111In]DTPA-octreotide. J Nucl Med 47:566-573
109. Miao Y, Owen NK, Whitener D, Gallazi F, Hoffman TJ, Quinn TP (2002) In vivo evaluation of 188Re-labeled alpha-melanocyte stimulating hormone peptide analogs for melanoma therapy. Int J Cancer 101:480-487
110. Michel MC, Beck-Sickinger A, Cox H, Doods HN, Herzog H, Larhammer D, Quirion R, Schwartz T, Westfall T (1998) XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol Rev 50:143-150
111. Mitra A, Nan A, Ghandehari H, McNeill E, Mulholland J, Line BR (2004) Technetium-99m-Labeled N-(2-hydroxypropyl) methacrylamide copolymers: synthesis, characterization, and in vivo biodistribution. Pharm Res 21:1153-1159
112. Mitra A, Mulholland J, Nan A, McNeill E, Ghandehari H, Line BR (2005) Targeting tumor angiogenic vasculature using polymer-RGD conjugates. J Control Release 102:191-201
113. Mountjoy KG, Robbins LS, Mortrud MT (1992) Cone RD. The cloning of a family of genes that encode the melanocortin receptors. Science 257:1248-1251
114. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verastegui E, Zlotnik A (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410:50-56
115. Nock B, Nikolopoulou A, Chiotellis E, Loudos G, Maintas D, Reubi JC, Maina T (2003) [99mTc]Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging. Eur J Nucl Med Mol Imaging 30:247-258
116. Nock BA, Nikolopoulou A, Galanis A, Cordopatis P, Waser B, Reubi JC, Maina T (2005a) Potent bombesin-like peptides for GRP-receptor targeting of tumors with 99mTc: a preclinical study. J Med Chem 48:100-110
117. Nock BA, Maina T, Behe M, Nikolopoulou A, Gotthardt M, Schmitt JS, Behr TM, Macke HR (2005b) CCK-2/gastrin receptor-targeted tumor imaging with 99mTc-labeled minigastrin analogs. J Nucl Med 46:1727-1736
118. Noguchi Y, Wu J, Duncan R et al (1998) Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Jpn J Cancer Res 89: 307-314
119. Poethko T, Schottelius M, Thumshirn G, Hersel U, Herz M, Henriksen G et al (2004a) Two-step methodology for high-yield routine radiohalogenation of peptides: 18F-labeled RGD and octreotide analogs. J Nucl Med 45:892-902
120. Poethko T, Schottelius M, Thumshirn G, Herz M, Haubner R, Henriksen G et al (2004b) Chemoselective pre-conjugate radiohalogenation of unprotected mono-and multimeric peptides via oxime formation. Radiochimica Acta 92:317-327
121. Reubi JC (2003) Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 24:389-427
122. Reubi JC, Waser B (2003) Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 30:781-793
123. Reubi JC, Schaer JC, Waser B (1997) Cholecystokinin(CCK)-A and CCK-B/gastrin receptors in human tumors. Cancer Res 57:1377-1386
124. Reubi JC, Waser B, Schaer JC et al (1998) Unsulfated DTPA-and DOTA-CCK analogs as specific high-affinity ligands for CCK-B receptor-expressing human and rat tissues in vitro and in vivo. Eur J Nucl Med 25:481-490
125. Reubi JC, Gugger M, Waser B, Schaer JC (2001) Y1-mediated effect of neuropeptide Y in cancer: breast carcinomas as targets. Cancer Res 61:4636-4641
126. Rogers BE, McLean SF, Kirkman RL, Della Manna D, Bright SJ, Olsen CC et al (1999) In vivo localization of [111In]-DTPA-D-Phe1-octreotide to human ovarian tumor xenografts induced to express the somatostatin receptor subtype 2 using an adenoviral vector. Clin Cancer Res 5:383-393
127. Schiffelers RM, Koning GA, ten Hagen TL et al (2003) Anti-tumor efficacy of tumor vasculaturetargeted liposomal doxorubicin. J Control Release 91:115-122
128. Schneider D, Engelman DM (2004) Involvement of transmembrane domain interactions in signal transduction by ?/? integrins. J Biol Chem 279:9840-9846
129. Schottelius M, Poethko T, Herz M, Reubi JC, Kessler H, Schwaiger M, Wester HJ (2004) First (18)F-labeled tracer suitable for routine clinical imaging of sst receptor-expressing tumors using positron emission tomography. Clin Cancer Res 10:3593-3606
130. Schottelius M, Reubi JC, Eltschinger V, Schwaiger M, Wester HJ (2005) N-terminal sugar conjugation and C-terminal Thr-for-Thr(ol) exchange in radioiodinated Tyr3-octreotide: effect on cellular ligand trafficking in vitro and tumor accumulation in vivo. J Med Chem 48:2778-2789
131. Schumacher T, Hofer S, Good S, Reubi JC, Maecke H, Mueller-Brand J et al (2002) Diffusible Brachytherapie mit 90Y-Substanz P bei High Grade Gliomen: Erste Beobachtungen. In: Brink I, Hogerle S, Moser E (ed) Nuklearmedizin als Paradigma molekularer Bildgebung. Blackwell, Berlin, p 68
132. Schuhmacher J, Zhang H, Doll J, Macke HR, Matys R, Hauser H, Henze M, Haberkorn U, Eisenhut M (2005) GRP receptor-targeted PET of a rat pancreas carcinoma xenograft in nude mice with a 68Ga-labeled bombesin(6-14) analog. J Nucl Med 46:691-699
133. Sharkey RM, Goldenberg DM(2005) Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J Nucl Med. 46(suppl 1):115S-127S
134. Siegrist W, Solca F, Stutz S et al (1989) Characterization of receptors for alpha-melanocyte stimulating hormone on human melanoma cells. Cancer Res 49:6352-6358
135. Signore A, Annovazzi A, Chianelli M, Corsetti F, Van deWiele C,Watherhouse RN (2001) Peptide radiopharmaceuticals for diagnosis and therapy. Eur J Nucl Med 28:1555-1565
136. Smith GP (1985) Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 228:1315-1317
137. Smith CJ, Volkert WA, Hoffman TJ (2005) Radiolabeled peptide conjugates for targeting of the bombesin receptor superfamily subtypes. Nucl Med Biol 32:733-740
138. Smith SV (2004) Molecular imaging with copper-64. J Inorg Biochem 98:1874-1901
139. Sprague JE, Peng Y, Sun X,Weisman GR,Wong EH, Achilefu S, Anderson CJ (2004) Preparation and biological evaluation of copper-64-labeled tyr3-octreotate using a cross-bridged macrocyclic chelator. Clin Cancer Res 10:8674-8682
140. Stefanidakis M, Koivunen E (2004) Peptide-mediated delivery of therapeutic and imaging agents into mammalian cells. Curr Pharm Des 10:3033-3044
141. Stein R, Goldenberg DM, Thorpe SR, Basu A, Mattes MJ (1995) Effects of radiolabeling monoclonal antibodies with a residualizing iodine radiolabel on the accretion of radioisotope in tumors. Cancer Res 55:3132-3139
142. Stolz B, Smith-Jones P, Albert R, Tolcsvai L, Briner U, Ruser G, Macke H,Weckbecker G, Bruns C (1997) Somatostatin analogues for somatostatin-receptor- mediated radiotherapy of cancer. Digestion 57 Suppl 1:17-21
143. Tatro JB, Reichlin S (1987) Specific receptors for alpha-melanocyte stimulating hormone are widely distributed in tissues of rodents. Endocrinology 121:1900-1907
144. Tatro JB, Atkins M, Mier JW et al (1990) Melanotropin receptors demonstrated in situ in human melanoma. J Clin Invest 85:1825-1832
145. Thumshirn G, Hersel U, Goodman SL, Kessler H (2003) Multimeric cyclic RGD peptides as potential tools for tumor targeting: solid-phase peptide synthesis and chemoselective oxime ligation. Chemistry 9:2717-2725
146. Van Hagen PM, BreemanWAP, Reubi JC, Postema, PTE, van den Anker-Lugtenburg PJ, Kwekkeboom DJ et al (1996) Visualization of the thymus by substance P receptor scintigraphy in man. Eur J Nucl Med 23:1508-1513
147. Velikyan I, Beyer GJ, Langstrom B (2004) Microwave-supported preparation of (68)Ga bioconjugates with high specific Radioactivity. Bioconjug Chem 15:554-560
148. Wank SA, Pisegna JR, de Weerth A (1994) Cholecystokinin receptor family. Molecular cloning, structure, and functional expression in rat, guinea pig, and human. Ann N Y Acad Sci 713: 49-66
149. Waser B, Eltschinger V, Linder K, Nunn A, Reubi JC (2007) Selective in vitro targeting of GRP and NMB receptors in human tumours with the new bombesin tracer 177Lu-AMBA. Eur J Nucl Med Mol Imaging 34:95-100
150. Wester HJ, Schottelius M, Scheidhauer K, Meisetschlager G, Herz M, Rau FC, Reubi JC, Schwaiger M (2003) PET imaging of somatostatin receptors: design, synthesis and preclinical evaluation of a novel 18F-labelled, carbohydrated analogue of octreotide. Eur J Nucl Med Mol Imaging 30:117-122
151. Wester HJ, Schottelius M, Poethko T, Bruus-Jensen K, Schwaiger M (2004) Radiolabeled carbohydrated somatostatin analogs: a review of the current status. Cancer Biother Radiopharm 19(2):231-244
152. Wester HJ, Kessler H (2005) Molecular targeting with peptides or peptide-polymer conjugates: just a question of size? J Nucl Med 46:1940-1945
153. Wieland HA, Hamilton BS, Krist B, Doods HN (2000) The role of NPY in metabolic homeostasis: Implications for obesity therapy. Expert Opin Investig Drugs 9:1327-1346
154. Wild D, Schmitt JS, Ginj M, Macke HR, Bernard BF, Krenning E et al (2003) DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging 30:1338-1347
155. Wild D, BeheM,Wicki A, Christofori G,Waser B, GotthardtMet al (2005a) Preclinical evaluation of an In-111 labeled Exendin-4 derivative, a very promising ligand for glucagons-like peptide-1 (GLP-1) receptor targeting. Mol Imaging 4:328
156. Wild D, Macke HR, Waser B, Reubi JC, Ginj M, Rasch H, Muller-Brand J, Hofmann M (2005b) 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5. Eur J Nucl Med Mol Imaging 32:724
157. Winter PM, Morawski AM, Caruthers SD et al (2003) Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles. Circulation 108: 2270-2274
158. Wu Y, Zhang X, Xiong Z, Cheng Z, Fisher DR, Liu S et al (2005) MicroPET imaging of glioma integrin v3 expression using 64Cu-labeled tetrameric RGD peptide. J Nucl Med 46: 1707-1718
159. Zhang X, Xiong Z,Wu Y, CaiW, Tseng JR, Gambhir SS, Chen X (2006) Quantitative PET imaging of tumor integrin v3 expression with 18F-FRGD2. J Nucl Med 47:113-121
160. Zinn KR, Buchsbaum DJ, Chaudhuri T et al (2000) Noninvasive monitoring of gene transfer using a reporter receptor imaged with a high affinity peptide radiolabeled with 99mTc or 188Re. J Nucl Med41:887-895